About akari therapeutics - AKTX
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.
AKTX At a Glance
Akari Therapeutics Plc
401 East Jackson Street
Tampa, Florida 33602
| Phone | 1-929-274-7510 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -17,338,423.19 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AKTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.462 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.431 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.144 |
AKTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,889,737.198 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AKTX Liquidity
| Current Ratio | 0.442 |
| Quick Ratio | 0.442 |
| Cash Ratio | 0.426 |
AKTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -35.149 |
| Return on Equity | -68.59 |
| Return on Total Capital | -59.619 |
| Return on Invested Capital | -68.59 |
AKTX Capital Structure
| Total Debt to Total Equity | 2.662 |
| Total Debt to Total Capital | 2.593 |
| Total Debt to Total Assets | 1.571 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |